Does Medicare cover Steglujan (ertugliflozin/linagliptin)?
Medicare coverage for Steglujan depends on whether it’s prescribed for a medically accepted indication and whether the drug is covered under the patient’s specific Part D plan (or as applicable, Part B in rare off-label/exception scenarios). Coverage is typically handled through Medicare Part D formularies, which list which drugs a plan will pay for and at what cost tier.
If you want to know your exact out-of-pocket cost, you generally need the specific Part D plan formulary (and sometimes prior authorization or step-therapy rules).
How to check if your specific Medicare plan covers Steglujan
You can confirm coverage by looking up Steglujan (brand) or its generic components on your plan’s formulary. Coverage typically varies by:
- Whether the plan covers the drug at all
- The tier it’s placed on (which affects copays/coinsurance)
- Whether the plan requires prior authorization
- Whether the plan requires step therapy (trying another diabetes medicine first)
Your prescriber can also submit documentation if prior authorization is required.
Will Medicare cover the generic version if Steglujan itself isn’t listed?
Often, if a plan doesn’t list a brand drug, it may still cover the generic equivalent (or may have different rules for brand vs. generic). For diabetes medications, plans sometimes prefer generics but can also cover brand products when clinically justified.
Is there any “patent/exclusivity” factor in whether Medicare covers it?
Medicare coverage decisions are usually separate from patents or exclusivity. Even when a drug is still under patent protection, Medicare Part D plans may cover it, but the patient’s cost-sharing depends on that plan’s formulary tiering and rules. For background on drug market status and related legal/market information, DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/ [1]
Quick next step
If you share your Medicare type (Part A/B vs Part D vs Medicare Advantage) and, if possible, your plan name, I can tell you what to look for in the formulary and what coverage hurdles (tier, prior authorization, step therapy) commonly apply.
Sources:
[1] https://www.drugpatentwatch.com/